News about "Granules India"

Granules India's Packaging Facility in US Completes FDA inspection with Zero Observations

Granules India Limited announced that its US step-down subsidiary, Granules Consumer Health, LLC, a wholly-owned subsidiary of Granules Pharmaceuticals, Inc., successfully completed a GMP inspection by the U.S. Food and Drug Administration (FDA) with zero observations.

Granules India | 05/12/2025 | By Darshana

Granules India and NIPER SAS Nagar Open Centre for Sustainable Pharma Solutions

Granules India and NIPER collaborate to open the Dr Chigurupati Centre of Excellence for empowering researchers with advanced facilities towards eco-friendly pharmaceutical manufacturing.

Granules India | 05/09/2025 | By Dineshwori |  139

Granules India Expands into Peptide Therapeutics with Acquisition of Senn Chemicals

Senn Chemicals AG brings advanced expertise in Liquid-Phase Peptide Synthesis (LPPS) and Solid-Phase Peptide Synthesis (SPPS), along with an established customer base in pharmaceuticals, cosmetics, and theragnostic industries.

Granules India | 24/02/2025 | By Aishwarya |  637

Granules India Gets ANDA Approval for Trazodone Tablets

Granules now has 65 ANDA approvals from the US FDA (64 final approvals and 1 tentative approval). The current annual US market for Trazodone tablets is approximately USD 128 Million.

Granules India | 12/08/2024 | By Aishwarya |  630

Granules India Records 2 Percent Growth in Revenue from Operations in Q4FY24

Granules India Ltd., has announced its financial results for the quarter and financial year ended March 31, 2024.

Granules India | 17/05/2024 | By Aishwarya |  895

Granules India Limited Gets ANDA Approval for Colchicine Capsules

Granules India Ltd. has declared that the US Food & Drug Administration (US FDA) has approved its Abbreviated New Drug Application (ANDA), filed by Granules Pharmaceuticals, Inc. (GPI), a wholly owned foreign subsidiary of the company, for Colchicine Capsules, 0.6 mg.

Granules India | 02/05/2024 | By Aishwarya |  649

Granules India Q2FY24 Revenue from Operations Stood at INR 11,895 Million up 3 percent YoY

Volume growth YoY was higher as compared to the value growth.

Granules India | 17/11/2023 | By Manvi |  651

Granules India Q1FY24 Revenue from Operations at INR 9855 mn down 3 Percent YoY

ROCE stood at 9.4 percent and net debt stood at INR 8,569 mn

Granules India | 10/08/2023 | By Manvi |  647

Granules Consumer Health completes US FDA audit with zero 483s

The packaging facility in Manassas is spread over 79,000 sq ft

Granules India | 22/03/2023 | By Sudeep Soparkar |  883

Granules India receives ANDA Approval for Losartan Potassium tabs

Granules now have a total of 54 ANDA approvals from the US FDA
<br />

Granules India | 27/02/2023 | By Sudeep Soparkar |  787